Advertisement
Home2024-01-11T09:26:42-05:00

Top Story

  • Medical Affairs
    April 1st, 2024

    US lawmakers have raised alarms about BGI, a major Chinese genomics firm, allegedly attempting to skirt regulatory oversight and potential political backlash by creating subsidiaries in the United States. Representatives Mike Gallagher and Raja Krishnamoorthi have specifically requested the inclusion of BGI's subsidiaries, Innomics and STOmics, [...]

Market Access

Advertisement

Featured Webinars

Handpicked Promotions & Highlights

Latest in Catalyst News powered by BioPharmCatalyst

04/22/2024 04:44 PM ET

ASLAN Pharmaceuticals Limited ASLN date announcement

ASLAN Pharmaceuticals Limited now has four catalyst announcements on the calendar after revealing the date on which they will release trial results for Eblasakimab (ASLAN004) - (TREK-DX). Now that the Phase 2b trial is completed, [...]

Read More
04/19/2024 04:43 PM ET

YS Biopharma Co. Ltd. YS earnings announcement

YS Biopharma Co. Ltd. fell in line with their revenue estimate but fell short of their EPS estimate, according to their recent quarterly earnings data. EPS was -$0.12, missing estimates by [...]

Read More
04/18/2024 04:44 PM ET

Vertex Pharmaceuticals Incorporated VRTX date announcement

Vertex Pharmaceuticals Incorporated, makers of Suzetrigine (VX-548), will be announcing their top-line results for the drug's recent NDA Filing trial on August 31, 2024. Our calculations show a 70.7% chance that the drug makes [...]

Read More
04/18/2024 04:44 PM ET

Immutep Limited IMMP results announcement

Immutep Limited released new information about their Phase 1 trial for IMP761. Our analysts provided the following summary:

"Trial planned for mid-2024."

This is one of three upcoming announcements for the company.

The market was [...]

Read More

Receive essential insights, resources and content direct to your inbox

Hit subscribe to stay informed!

Go to Top